First Quadrant’s Inovio Pharmaceuticals INO Stock Holding History

First Quadrant’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,950	Closed	-$253K	–	525
2021 Q3	$253K	Buy	+2,950	New	+$296K	0.03%	318

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Quadrant's INO Position: Q4 2021 in Review

First Quadrant sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 2,950 shares — an estimated $253K sold.

First Quadrant first reported a position in INO in Q3 2021 and held it in 1 quarter. The position peaked at $253K in Q3 2021. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

First Quadrant reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
First Quadrant sold 2,950 Inovio Pharmaceuticals shares in Q4 2021, an estimated $253K.
First Quadrant first reported a position in Inovio Pharmaceuticals in Q3 2021 and held it in 1 quarter.
First Quadrant's Inovio Pharmaceuticals position peaked at $253K in Q3 2021.
208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.